Conference Call with Piramal Pharma Ltd. Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Piramal Pharma announced Q1FY25 results: Revenue from Operations grew by 12% YoY to 1,951 crore in Q1FY25, driven by robust high-teen growth in the CDMO business and steady double-digit growth in the ICH business EBITDA grew by 31% YoY to Rs 221 crore with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24, driven by operating leverage, cost optimization measures and superior revenue mix Best-in-class quality track record - Successfully closed the USFDA inspections at Lexington facility (US) with an EIR# and at PPDS facility (Analytical Services, India) with zero observations Piramal Pharma was honoured as one of the top Sustainable Organizations at the 3rd edition of “Times Now Global Sustainability Alliance Sustainable Organizations 2024” Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also seeing good demand for our differentiated offerings with increase in customer enquiries and visits. In our CHG business, our planned expansion for inhalation anesthesia portfolio is on track and is expected to get commercialized in FY26. Our India Consumer Healthcare business is also delivering steady growth driven by power brands and strong traction in e-commerce channel. As a responsible organisation, we are taking good strides in our journey towards building sustainable operations. Our continuous efforts in quality and compliance bore fruits with successful closure of USFDA inspections at two of our facilities at Lexington (USA) and PPDS (Analytical Services, India). Historically our H2 outperforms H1, both in terms of revenue and profitability, and we expect this trend to continue in FY25. We intend to further build on to the good start that we have had to the financial year.” Result PDF